80 related articles for article (PubMed ID: 24433184)
21. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
22. Identification and functional characterization of ASK/Dbf4, a novel cell survival gene in cutaneous melanoma with prognostic relevance.
Nambiar S; Mirmohammadsadegh A; Hassan M; Mota R; Marini A; Alaoui A; Tannapfel A; Hegemann JH; Hengge UR
Carcinogenesis; 2007 Dec; 28(12):2501-10. PubMed ID: 17768177
[TBL] [Abstract][Full Text] [Related]
23. Sox10 is expressed in primary melanocytic neoplasms of various histologies but not in fibrohistiocytic proliferations and histiocytoses.
Shin J; Vincent JG; Cuda JD; Xu H; Kang S; Kim J; Taube JM
J Am Acad Dermatol; 2012 Oct; 67(4):717-26. PubMed ID: 22325460
[TBL] [Abstract][Full Text] [Related]
24. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
25. Reduced lecithin:retinol acyltransferase expression in human breast cancer.
Sheren-Manoff M; Shin SJ; Su D; Bok D; Rando RR; Gudas LJ
Int J Oncol; 2006 Nov; 29(5):1193-9. PubMed ID: 17016651
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma.
Rangel J; Torabian S; Shaikh L; Nosrati M; Baehner FL; Haqq C; Leong SP; Miller JR; Sagebiel RW; Kashani-Sabet M
J Clin Oncol; 2006 Oct; 24(28):4565-9. PubMed ID: 17008696
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
28. P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters.
Poyraz A; Akyürek N; Gönül II; Erdem O
J Exp Clin Cancer Res; 2004 Dec; 23(4):625-31. PubMed ID: 15743033
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma.
Väisänen A; Kallioinen M; Taskinen PJ; Turpeenniemi-Hujanen T
J Pathol; 1998 Sep; 186(1):51-8. PubMed ID: 9875140
[TBL] [Abstract][Full Text] [Related]
30. Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study.
Nazarian RM; Prieto VG; Elder DE; Duncan LM
J Cutan Pathol; 2010 Apr; 37 Suppl 1():41-7. PubMed ID: 20482674
[TBL] [Abstract][Full Text] [Related]
31. The protein expression of TRP-1 and galectin-1 in cutaneous malignant melanomas.
Bolander A; Agnarsdóttir M; Strömberg S; Ponten F; Hesselius P; Uhlen M; Bergqvist M
Cancer Genomics Proteomics; 2008; 5(6):293-300. PubMed ID: 19287070
[TBL] [Abstract][Full Text] [Related]
32. Nodal blue nevus: a pitfall in lymph node biopsies.
Dohse L; Ferringer T
J Cutan Pathol; 2010 Jan; 37(1):102-4. PubMed ID: 19615001
[TBL] [Abstract][Full Text] [Related]
33. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of P-cadherin expression in melanocytic skin tumours analysed by high-throughput tissue microarrays.
Bauer R; Wild PJ; Meyer S; Bataille F; Pauer A; Klinkhammer-Schalke M; Hofstaedter F; Bosserhoff AK
J Clin Pathol; 2006 Jul; 59(7):699-705. PubMed ID: 16565225
[TBL] [Abstract][Full Text] [Related]
35. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma.
Chen H; Takahara M; Oba J; Xie L; Chiba T; Takeuchi S; Tu Y; Nakahara T; Uchi H; Moroi Y; Furue M
J Dermatol Sci; 2011 Oct; 64(1):39-44. PubMed ID: 21767935
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
38. Nuclear 8-hydroxy-2'-deoxyguanosine as survival biomarker in patients with cutaneous melanoma.
Murtas D; Piras F; Minerba L; Ugalde J; Floris C; Maxia C; Demurtas P; Perra MT; Sirigu P
Oncol Rep; 2010 Feb; 23(2):329-35. PubMed ID: 20043092
[TBL] [Abstract][Full Text] [Related]
39. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
40. Metallothionein-overexpression as a prognostic marker in melanoma.
Weinlich G
G Ital Dermatol Venereol; 2009 Feb; 144(1):27-38. PubMed ID: 19218909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]